BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25349073)

  • 1. Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria.
    Zhu Q; Wang L; Tannenbaum S; Ricci A; DeFusco P; Hegde P
    Breast Cancer Res; 2014 Oct; 16(5):456. PubMed ID: 25349073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
    Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer: assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography.
    Zhu Q; DeFusco PA; Ricci A; Cronin EB; Hegde PU; Kane M; Tavakoli B; Xu Y; Hart J; Tannenbaum SH
    Radiology; 2013 Feb; 266(2):433-42. PubMed ID: 23264349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
    Tran WT; Gangeh MJ; Sannachi L; Chin L; Watkins E; Bruni SG; Rastegar RF; Curpen B; Trudeau M; Gandhi S; Yaffe M; Slodkowska E; Childs C; Sadeghi-Naini A; Czarnota GJ
    Br J Cancer; 2017 May; 116(10):1329-1339. PubMed ID: 28419079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.
    Qu YH; Zhu HT; Cao K; Li XT; Ye M; Sun YS
    Thorac Cancer; 2020 Mar; 11(3):651-658. PubMed ID: 31944571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.
    Takada M; Sugimoto M; Ohno S; Kuroi K; Sato N; Bando H; Masuda N; Iwata H; Kondo M; Sasano H; Chow LW; Inamoto T; Naito Y; Tomita M; Toi M
    Breast Cancer Res Treat; 2012 Jul; 134(2):661-70. PubMed ID: 22689089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
    Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
    BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
    Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
    Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients.
    Baumgartner A; Tausch C; Hosch S; Papassotiropoulos B; Varga Z; Rageth C; Baege A
    Breast; 2018 Jun; 39():19-23. PubMed ID: 29518677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Functional Differences in Malignant and Benign Breast Lesions and Improvement of Diagnostic Accuracy by Using US-guided Diffuse Optical Tomography in Conjunction with Conventional US.
    Zhu Q; Ricci A; Hegde P; Kane M; Cronin E; Merkulov A; Xu Y; Tavakoli B; Tannenbaum S
    Radiology; 2016 Aug; 280(2):387-97. PubMed ID: 26937708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
    Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Intravoxel Incoherent Motion Diffusion Weighted Imaging in the Pre-treatment Prediction and Early Response Monitoring to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Che S; Zhao X; Ou Y; Li J; Wang M; Wu B; Zhou C
    Medicine (Baltimore); 2016 Jan; 95(4):e2420. PubMed ID: 26825883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
    Choi BB; Kim SH
    Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization.
    Zhu Q; Tannenbaum S; Hegde P; Kane M; Xu C; Kurtzman SH
    Neoplasia; 2008 Oct; 10(10):1028-40. PubMed ID: 18813360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
    Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
    Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
    Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
    Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
    Lee HJ; Song IH; Seo AN; Lim B; Kim JY; Lee JJ; Park IA; Shin J; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2015 Feb; 22(2):392-400. PubMed ID: 25192679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.